The case for Novo Nordisk's oral Wegovy is being pressed from the top, but the market's response has been to sell. Shares fell after the company's chief executive defended the pill's economics publicly, even as lower prices were already working against the sales line. The tension is plain: executive confidence is running ahead of what Wall Street can verify in the numbers.
What the CEO is defending
Novo Nordisk's chief executive acknowledged the commercial pressure on Wegovy's pill form while arguing that the product's economics remain sound. The defense came precisely as lower prices worked their way into the sales line. This raises the harder question of whether volume gains can eventually offset that margin pressure. The CEO's position is that they can. The market's position, expressed through the share price, is skepticism.
Eli Lilly and the competitive pressure
The case for Novo Nordisk is complicated by intensifying competition from Eli Lilly. Wall Street's doubt is partly structural: when a rival is pressing harder into the same category, a chief executive defending unit economics is trying to win an argument the competitive calendar may not allow. The risk is that price concessions become the ongoing cost of staying relevant rather than a temporary move, and that growth which looked sustainable before Lilly accelerated no longer does now.
The counterargument
The counterargument deserves a fair hearing. An oral formulation is a different proposition from the injectable version the company built its franchise on. Novo Nordisk can argue that the addressable market for a Wegovy pill represents a genuinely separate patient population, not simply the same pool Eli Lilly is contesting. If that holds, the lower prices may be a short-term cost of building a new oral category rather than evidence of structural erosion. Some investors will hold that view.
On balance
On balance, what the reported facts resolve is narrow. Prices are lower, sales have felt it, and the CEO's public defense has not persuaded Wall Street that a promising path back to sustainable growth exists. The line to watch is whether pill volumes rise at a rate that supports the economics Novo Nordisk is defending. The shares fell, and that verdict has not yet been walked back.